Wealth Enhancement Advisory Services
PCRX icon

Wealth Enhancement Advisory Services’s Pacira BioSciences PCRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$311K Buy
12,221
+833
+7% +$19.7K ﹤0.01% 3170
2026
Q1 		$259K Buy
11,388
+1,933
+20% +$43K ﹤0.01% 2920
2025
Q4 		$239K Buy
9,455
+43
+0.5% +$1.02K ﹤0.01% 3123
2025
Q3 		$222K Buy
9,412
+153
+2% +$3.76K ﹤0.01% 3037
2025
Q2 		$215K Buy
+9,259
New +$233K ﹤0.01% 2932

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealth Enhancement Advisory Services's PCRX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Pacira BioSciences (PCRX) stake by 7.3% in Q2 2026, buying an estimated $19.7K and bringing the position to 12,221 shares worth $311K. The position accounts for ﹤0.01% of the portfolio, ranked #3170.

Wealth Enhancement Advisory Services first reported a position in PCRX in Q2 2025 and has held it in 5 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 12,221 shares of Pacira BioSciences worth $311K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 833 Pacira BioSciences shares in Q2 2026, an estimated $19.7K.
  • Pacira BioSciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3170 holding.
  • Wealth Enhancement Advisory Services first reported a position in Pacira BioSciences in Q2 2025 and has held it in 5 quarters since.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.